To provide the information your oncologist is not telling you or doesn't have the time to!
Here, we delve into the dynamic world of cutting-edge cancer treatments and therapies. Stay informed about groundbreaking advancements in cancer care, from emerging therapies to novel treatment modalities. Discover how science and technology are shaping the future of oncology, offering new hope and possibilities to those affected by cancer. Join us as we explore innovative approaches that hold the promise of brighter tomorrows for patients and their families.
A recent New England Journal of Medicine study introduces asciminib, a new treatment for Chronic Myeloid Leukemia (CML) that shows improved effectiveness and fewer side effects compared to current therapies. This post will explain the study’s findings and what they mean for patients and caregivers, highlighting how asciminib could offer a better option for those newly diagnosed with …
Sophia’s Story I’ll never forget the day I met Sophia. She sat in my clinic, a mother of two and a dedicated teacher, but her eyes were clouded with fear. When she first received the news that she had high-risk bladder cancer, she told me she felt like the ground had shifted beneath her feet. …
Gene Therapy: A Promising Future As I continue to highlight key aspects of SCD this September, I will shift the focus to the exciting advancements in research and treatment. Recent breakthroughs offer new hope and possibilities for individuals living with this condition. In this installment, we’ll explore the latest research developments, including innovative therapies and …
A recent article published in the New England Journal of Medicine (NEJM) demonstrated higher response, longer progression free survival and overall survival in patients with unresectable or metastatic leiomyosarcoma. A treatment protocol that we’ve been doing for at least 1-2 years prior given the known higher response rate reported at conferences. This is a new …
EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) EGFR (epidermal growth factor receptor) is a protein located on the surface of cells that regulates their growth and division. Mutations in the EGFR gene can lead to uncontrolled cell growth and are commonly found in various cancers, including non-small cell lung cancer (NSCLC). In patients with unresectable stage …
Multiple myeloma (MM) is a type of blood cancer that originates in the plasma cells, which are a type of white blood cell found in the bone marrow. Plasma cells are responsible for producing antibodies that help fight infections. In multiple myeloma, abnormal plasma cells multiply uncontrollably, leading to a range of complications. Key Characteristics …
When it comes to battling a rare and aggressive cancer like synovial sarcoma, the treatment options have often been limited—until now. The FDA’s recent approval of Tecelra (Amafi-Cel), the first gene therapy for adults with metastatic synovial sarcoma, not only provides new hope for patients who’ve exhausted other options but also paves the way for …
New exciting data published in the NEJM demonstrating improved for a specific subset of lung cancer patients but also demonstrating the power of targeted therapies when we can identify a driver mutation that is sensitive or “actionable” with a treatment to shut down its specific function. Exciting! Non-Small Cell Lung Cancer (NSCLC) represents a significant …
Last week, we heard the tremendous news regarding the FDA approval of Lifileucel for metastatic melanoma refractory to prior immunotherapy checkpoint inhibitor therapy. In this article, let’s focus on an uncommon melanoma subtype in the general population that we routinely see in practice. In the realm of oncology, the fight against cancer continually evolves, marked …
The journey of understanding and treating metastatic bladder cancer has been marked by both challenges and triumphs. This cancer, which starts in the lining of the bladder and spreads beyond, represents a critical area in oncology due to its high incidence and aggressive nature. As per the latest statistics, metastatic bladder cancer accounts for about …